EDIT earnings analysis
What we found in EDIT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Editas Medicine reported a significant decline in revenue and a net loss improvement in Q1 of 2026, marking a loss of $24.98 million, or $0.26 per share, down from $76.09 million, or $0.92 per share in the same quarter last year. Revenue dropped drastically to $2.83 million, driven by the conclusion of a collaboration agreement, while cash reserves dipped to $123.6 million, affirming sufficient funds to support operations until Q3 2027.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Improved EPS Figures
- EPS improved to -$0.26 vs. -$0.92 from last year, a 72% reduction in losses.
- Reduced Operating Expenses
- Total operating expenses fell to $27.83 million, a decrease of 66% from $80.82 million in the prior year.
- Improved R&D Cost Efficiency
- Research and development expenses decreased by $8.99 million to $17.6 million, a 34% reduction year-on-year.
- Cash Reserves Sufficient to Fund Operations
- Cash and cash equivalents stood at $123.6 million, expected to last until Q3 2027.
- No Restructuring Charges
- No restructuring and impairment charges incurred, a significant drop from $40.85 million in the prior year.
- Collaboration Income From Vertex
- Ongoing revenues anticipated from Vertex, with $10 million received in license fees this quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Heavily Dependent on Licensing Revenues
- The majority of revenue generated from Vertex License Agreement leads to uncertainty due to lack of product sales.
- Increased Costs with Future Development
- Future clinical development costs for EDIT-401 may rise significantly without assured funding.
- Patent Rulings Affecting Intellectual Property
- Ongoing legal disputes regarding patent validity and ownership may impact business operations.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.26
What they said about what is next.
No explicit forward guidance provided in this quarterly report.
The filing reads worse than the one before it.
What came before.
- 10-K · March 9, 2026
- Editas pivoted from ex vivo commercialization to an in vivo-focused strategy, nominating EDIT-401 in September 2025 as its lead in vivo candidate and targeting an IND submission by mid-2026 with early human…
- 10-Q · November 10, 2025
- Editas Medicine reported significant improvements in Q3 2025, showcasing a stunning revenue increase to $7.543 million from just $61 thousand in Q3 2024, marking a substantial year-over-year rise. The company's net loss…
- 10-Q · August 12, 2025
- Editas reported Q2 collaboration revenue of $3.578M (vs. $0.513M a year ago) and GAAP net loss of $53.235M (-$0.63/share). Revenue improved materially year-over-year but declined sequentially vs. Q1 2025; operating loss…
- 10-Q · May 8, 2024
- Editas reported collaboration revenue of $1.135 million and a net loss of $61.95 million (EPS $(0.76)) for the quarter ended March 31, 2024. Revenue collapsed versus the year-ago quarter ($9.851 million) while operating…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing EDIT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever